Fumiko Arakawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Fumiko Arakawa has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Hiroaki Miyoshi
Department of Pathology Kurume University School of Medicine Kurume Japan
3 shared publications - Kazutaka Nakashima
Division of Pathology, Kurume University, Kurume, Japan
2 shared publications - Koichi Ohshima
Department of Pathology, Kurume University School of Medicine, Kurume, Japan
2 shared publications - Noriaki Yoshida
Department of Clinical Studies, Radiation Effects Research Foundation, Hiroshima, Japan
2 shared publications Yoshio Misumi
Second Department of Biochemistry, School of Medicine, Fukuoka University 7-45-1 Nanakuma, Jonan-ku, Fukuoka 814-80
2 shared publications- Akira Matsunaga
General Medical Research Center, Faculty of Medicine, Fukuoka University
1 shared publication
Latest Publications
- Open Access
- 3 September 2021
- Published by Wiley in Cancer Medicine
- Vol. 10 (19) , 6786-6794
Expression of telomerase reverse transcriptase in peripheral T‐cell lymphoma
Telomere length is maintained by the activation of telomerase, which causes continuous cell division and proliferation in many carcinomas. A catalytic reverse transcriptase protein (TERT) encoded by the TERT gene plays a critical role in the activation of telomerase. We performed a molecular and pathological analysis of the TERT against three different peripheral T‐cell lymphoma (PTCL) subtypes: PTCL, not otherwise specified (PTCL‐NOS), angioimmunoblastic T‐cell lymphoma (AITL), and adult T‐cell leukemia/lymphoma (ATLL). Immunohistochemical analysis demonstrated TERT expression in 31% of AITL, 11% of PTCL‐NOS, and 5% of ATLL. Among them, AITL frequently showed high TERT expression with statistical significance. TERT promoter mutation analysis and genomic copy number evaluation were performed. TERT promoter mutation was observed in two cases of PTCL‐NOS (2/40) and not in other PTCLs. Genome copy number amplification was detected in 33% of PTCL‐NOS, 33% of AITL, and 50% of ATLL cases. We evaluated the relationship between the analyzed TERT genomic abnormalities and protein expression; however, no apparent relationship was observed. Furthermore, immunostaining showed TERT expression in the PTCL cytoplasm, suggesting the existence of mechanisms other than the maintenance of telomere length. Statistical analysis of the effect of TERT expression on the prognosis in PTCL cases revealed that TERT expression tended to have a poor prognosis in PTCL‐NOS. Since TERT expression was not an independent factor in multivariate analysis, further research will be needed to clarify the poor prognosis of PTCL‐NOS in TERT expression.
- 3 September 2021
- Published by Wiley in Cancer Medicine
- Vol. 10 (19) , 6786-6794
Open AccessExpression of telomerase reverse transcriptase in peripheral T‐cell lymphoma
Telomere length is maintained by the activation of telomerase, which causes continuous cell division and proliferation in many carcinomas. A catalytic reverse transcriptase protein (TERT) encoded by the TERT gene plays a critical role in the activation of telomerase. We performed a molecular and pathological analysis of the TERT against three different peripheral T‐cell lymphoma (PTCL) subtypes: PTCL, not otherwise specified (PTCL‐NOS), angioimmunoblastic T‐cell lymphoma (AITL), and adult T‐cell leukemia/lymphoma (ATLL). Immunohistochemical analysis demonstrated TERT expression in 31% of AITL, 11% of PTCL‐NOS, and 5% of ATLL. Among them, AITL frequently showed high TERT expression with statistical significance. TERT promoter mutation analysis and genomic copy number evaluation were performed. TERT promoter mutation was observed in two cases of PTCL‐NOS (2/40) and not in other PTCLs. Genome copy number amplification was detected in 33% of PTCL‐NOS, 33% of AITL, and 50% of ATLL cases. We evaluated the relationship between the analyzed TERT genomic abnormalities and protein expression; however, no apparent relationship was observed. Furthermore, immunostaining showed TERT expression in the PTCL cytoplasm, suggesting the existence of mechanisms other than the maintenance of telomere length. Statistical analysis of the effect of TERT expression on the prognosis in PTCL cases revealed that TERT expression tended to have a poor prognosis in PTCL‐NOS. Since TERT expression was not an independent factor in multivariate analysis, further research will be needed to clarify the poor prognosis of PTCL‐NOS in TERT expression.
- 2 September 2021
- Published by Wiley in Pathology International
- Vol. 71 (11) , 765-770
The first case of methotrexate‐associated lymphoproliferative disorder presenting as follicular T‐cell lymphoma
This is the first case of follicular T‐cell lymphoma (FTCL) presenting as methotrexate‐associated lymphoproliferative disorders (MTX‐LPDs). A 69‐year‐old man treated rheumatoid arthritis with methotrexate presented with cervical swelling, hoarseness and fever. Imaging studies revealed multiple lymphadenopathy and lymphoma was suspected. Lymph node biopsy was performed to confirm the diagnosis. Pathologically, the lymph node was composed of atypical lymphocytes with a follicular growth pattern and area of necrosis. Immunohistochemical examination showed the atypical lymphocytes were positive for CD3, CD4, programmed cell death protein 1, and inducible T‐cell co‐stimulator. These findings are consistent with FTCL. During hospitalization, the patient's fever subsided and cervical lymphadenopathy improved, probably due to discontinuation of MTX. Here we presented the first case of FTCL presenting as MTX‐LPDs. The T‐cell phenotype MTX‐LPDs are relatively rare and accounts for only 3.4%–6.3% of all MTX‐LPD cases. Therefore, detailed clinicopathological features have not been clarified sufficiently. It is hoped that similar cases should be accumulated and studied to better understand the clinical and pathological features of this condition.
- 2 September 2021
- Published by Wiley in Pathology International
- Vol. 71 (11) , 765-770
The first case of methotrexate‐associated lymphoproliferative disorder presenting as follicular T‐cell lymphoma
This is the first case of follicular T‐cell lymphoma (FTCL) presenting as methotrexate‐associated lymphoproliferative disorders (MTX‐LPDs). A 69‐year‐old man treated rheumatoid arthritis with methotrexate presented with cervical swelling, hoarseness and fever. Imaging studies revealed multiple lymphadenopathy and lymphoma was suspected. Lymph node biopsy was performed to confirm the diagnosis. Pathologically, the lymph node was composed of atypical lymphocytes with a follicular growth pattern and area of necrosis. Immunohistochemical examination showed the atypical lymphocytes were positive for CD3, CD4, programmed cell death protein 1, and inducible T‐cell co‐stimulator. These findings are consistent with FTCL. During hospitalization, the patient's fever subsided and cervical lymphadenopathy improved, probably due to discontinuation of MTX. Here we presented the first case of FTCL presenting as MTX‐LPDs. The T‐cell phenotype MTX‐LPDs are relatively rare and accounts for only 3.4%–6.3% of all MTX‐LPD cases. Therefore, detailed clinicopathological features have not been clarified sufficiently. It is hoped that similar cases should be accumulated and studied to better understand the clinical and pathological features of this condition.
- Open Access
- 1 August 2019
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 58 (15) , 2159-2166
Clinical Features, Pathological Features, and Treatment Outcomes of 22 Patients with Aggressive Adult T-cell Leukemia-lymphoma Treated with a Humanized CCR4 Antibody (Mogamulizumab) at a Single Institution during a 6-year Period (2012-2018)
Objective To elucidate the clinical impact of humanized CCR4 antibody (mogamulizumab) on adult T-cell leukemia-lymphoma (ATL), we retrospectively analyzed the clinical and pathological features and treatment outcomes of aggressive ATL. Methods Twenty-two patients (median age: 65 years) with aggressive ATL (acute- [n=16] or lymphoma-type [n=6]) had their characteristics analyzed. All cases were treated with mogamulizumab at our institution from 2012 to 2018. In addition, we subjected 14 specimens of ATL to histological, immunological, and genetic analyses. Results Regarding the patient outcomes, the overall response rates were 68.1% and 31.8% after 4 and 8 courses (or after the final courses), respectively. The median overall survival (OS) was 95.5 days, while the OS rates at 6 and 12 months were 31.5% and 21.1%, respectively. Concerning patient pathological characteristics, 6 of the 14 patients examined (42.9%) had CCR4 mutations. Regarding the clinicopathological findings related to the mogamulizumab response, notably, the cases with somatic CCR4 mutation tended to have a poorer response (16.7%) than those with wild-type CCR 4 (62.5%) after 4 cycles of mogamulizumab. Furthermore, the CCR4 global score tended to be higher in the responder cases than in the non-responder cases. Conclusion The present findings suggest that the CCR4 expression may be related to the mogamulizumab response, although no other significant predictive markers were identified in this study. Further studies will be needed in order to identify more markers related to the mogamulizumab response.
- 1 August 2019
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 58 (15) , 2159-2166
Open AccessClinical Features, Pathological Features, and Treatment Outcomes of 22 Patients with Aggressive Adult T-cell Leukemia-lymphoma Treated with a Humanized CCR4 Antibody (Mogamulizumab) at a Single Institution during a 6-year Period (2012-2018)
Objective To elucidate the clinical impact of humanized CCR4 antibody (mogamulizumab) on adult T-cell leukemia-lymphoma (ATL), we retrospectively analyzed the clinical and pathological features and treatment outcomes of aggressive ATL. Methods Twenty-two patients (median age: 65 years) with aggressive ATL (acute- [n=16] or lymphoma-type [n=6]) had their characteristics analyzed. All cases were treated with mogamulizumab at our institution from 2012 to 2018. In addition, we subjected 14 specimens of ATL to histological, immunological, and genetic analyses. Results Regarding the patient outcomes, the overall response rates were 68.1% and 31.8% after 4 and 8 courses (or after the final courses), respectively. The median overall survival (OS) was 95.5 days, while the OS rates at 6 and 12 months were 31.5% and 21.1%, respectively. Concerning patient pathological characteristics, 6 of the 14 patients examined (42.9%) had CCR4 mutations. Regarding the clinicopathological findings related to the mogamulizumab response, notably, the cases with somatic CCR4 mutation tended to have a poorer response (16.7%) than those with wild-type CCR 4 (62.5%) after 4 cycles of mogamulizumab. Furthermore, the CCR4 global score tended to be higher in the responder cases than in the non-responder cases. Conclusion The present findings suggest that the CCR4 expression may be related to the mogamulizumab response, although no other significant predictive markers were identified in this study. Further studies will be needed in order to identify more markers related to the mogamulizumab response.
- 1 March 2003
- Published by Wiley in The Journal of Dermatology
- Vol. 30 (3) , 181-188
Gamma Interferon Gene Transfection Efficiently Inhibits Proliferation of Neurofibroma Cell Lines In vitro
Primarily isolated neurofibroma cell lines and a human dermal fibroblast cell line were transfected with human gamma interferon gene in vitro, and changes in the cell proliferation rates were investigated. The proliferation rates of both cell lines were remarkably suppressed after the gene transfection. In particular, the neurofibroma cell lines almost stopped proliferating five days after gene transfection. The tritium thymidine uptake of the fibroblast cell line was almost abolished three days after gene transfection. The culture media from both of the gene‐transfected cell lines contained a measurable gamma interferon concentration as late as five days after transfection, this was detected by an enzyme‐linked immunosorbent assay. These data suggest that gamma interferon gene therapy might be a possible treatment for intractable or inoperable neurofibromas in patients with von Recklinghausen's disease in the future.
- 1 March 2003
- Published by Wiley in The Journal of Dermatology
- Vol. 30 (3) , 181-188
Gamma Interferon Gene Transfection Efficiently Inhibits Proliferation of Neurofibroma Cell Lines In vitro
Primarily isolated neurofibroma cell lines and a human dermal fibroblast cell line were transfected with human gamma interferon gene in vitro, and changes in the cell proliferation rates were investigated. The proliferation rates of both cell lines were remarkably suppressed after the gene transfection. In particular, the neurofibroma cell lines almost stopped proliferating five days after gene transfection. The tritium thymidine uptake of the fibroblast cell line was almost abolished three days after gene transfection. The culture media from both of the gene‐transfected cell lines contained a measurable gamma interferon concentration as late as five days after transfection, this was detected by an enzyme‐linked immunosorbent assay. These data suggest that gamma interferon gene therapy might be a possible treatment for intractable or inoperable neurofibromas in patients with von Recklinghausen's disease in the future.
- 1 September 1996
- Published by Oxford University Press (OUP) in The Journal of Biochemistry
- Vol. 120 (3) , 657-662
Cloning and Sequencing of the VH and YK Genes of an Anti-CD3 Monoclonal Antibody, and Construction of a Mouse/Human Chimeric Antibody
Mouse monoclonal antibodies against CD3 on human T lymphocytes have been used for therapy in organ-transplant patients as a potent immunosuppressive agent or for treatment of cancer as a potent T cell activating agent. However, an inherent problem in their in vivo application is the human anti-mouse antibody response. In this study, we cloned and sequenced the variable region genes of the heavy and light chains (VH and VK) of a mouse anti-human CD3 monoclonal antibody (OKT3) using the reverse transcription-polymerase chain reaction method. Then, we constructed a mouse/human chimeric antibody, designated as Ch OKT3, by fusing the OKT3 VH and VK genes to the human heavy and light chain constant region genes (Cγ1 and CK) derived from a human plasma cell leukemia line (ARH77), respectively. The chimeric gene constructs were sequentially co-transfected into mouse non-Ig-producing hybridoma cells (Sp2/0) by electroporation. The Ch OKT3 antibody thus prepared bound to human peripheral blood mononuclear cells and competitively inhibited the binding of the parental MAb OKT3 to the blood mononuclear cells, indicating that this chimeric antibody seems to be suitable for in vivo therapeutic approaches.
- 1 September 1996
- Published by Oxford University Press (OUP) in The Journal of Biochemistry
- Vol. 120 (3) , 657-662
Cloning and Sequencing of the VH and YK Genes of an Anti-CD3 Monoclonal Antibody, and Construction of a Mouse/Human Chimeric Antibody
Mouse monoclonal antibodies against CD3 on human T lymphocytes have been used for therapy in organ-transplant patients as a potent immunosuppressive agent or for treatment of cancer as a potent T cell activating agent. However, an inherent problem in their in vivo application is the human anti-mouse antibody response. In this study, we cloned and sequenced the variable region genes of the heavy and light chains (VH and VK) of a mouse anti-human CD3 monoclonal antibody (OKT3) using the reverse transcription-polymerase chain reaction method. Then, we constructed a mouse/human chimeric antibody, designated as Ch OKT3, by fusing the OKT3 VH and VK genes to the human heavy and light chain constant region genes (Cγ1 and CK) derived from a human plasma cell leukemia line (ARH77), respectively. The chimeric gene constructs were sequentially co-transfected into mouse non-Ig-producing hybridoma cells (Sp2/0) by electroporation. The Ch OKT3 antibody thus prepared bound to human peripheral blood mononuclear cells and competitively inhibited the binding of the parental MAb OKT3 to the blood mononuclear cells, indicating that this chimeric antibody seems to be suitable for in vivo therapeutic approaches.
- Open Access
- 1 November 1995
- Published by Elsevier in Journal of Lipid Research
- Vol. 36 (11) , 2329-2343
Two novel point mutations in the lecithin:cholesterol acyltransferase (LCAT) gene resulting in LCAT deficiency: LCAT (G873 deletion) and LCAT (Gly344–>Ser)
- 1 November 1995
- Published by Elsevier in Journal of Lipid Research
- Vol. 36 (11) , 2329-2343
Open AccessTwo novel point mutations in the lecithin:cholesterol acyltransferase (LCAT) gene resulting in LCAT deficiency: LCAT (G873 deletion) and LCAT (Gly344–>Ser)
- 1 July 1992
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression
- Vol. 1131 (3) , 333-336
Molecular cloning and sequence analysis of human dipeptidyl peptidase IV, a serine proteinase on the cell surface
- 1 July 1992
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression
- Vol. 1131 (3) , 333-336
Molecular cloning and sequence analysis of human dipeptidyl peptidase IV, a serine proteinase on the cell surface